Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW.

World J Urol. 2012 Apr;30(2):149-55. doi: 10.1007/s00345-011-0804-y. Epub 2011 Dec 28.

2.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
3.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

4.

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ.

World J Urol. 2012 Apr;30(2):181-7. doi: 10.1007/s00345-011-0818-5. Epub 2011 Dec 31.

5.

Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.

Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, Largo R, Wild P, Sulser T, Hermanns T.

BJU Int. 2016 Mar;117(3):401-8. doi: 10.1111/bju.13314. Epub 2015 Oct 5.

6.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
7.

Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ.

Eur J Cancer. 2012 Aug;48(12):1809-15. doi: 10.1016/j.ejca.2012.02.002. Epub 2012 Mar 7.

PMID:
22406050
8.

European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.

Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.

BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.

PMID:
26833820
9.

Prostate cancer risk assessment tools in an unscreened population.

Lundon DJ, Kelly BD, Foley R, Loeb S, Fitzpatrick JM, Watson RW, Rogers E, Durkan GC, Walsh K.

World J Urol. 2015 Jun;33(6):827-32. doi: 10.1007/s00345-014-1365-7. Epub 2014 Aug 5.

PMID:
25091862
10.

Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.

Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM, Bangma CH, Ng CF.

Int Urol Nephrol. 2016 Oct;48(10):1631-7. doi: 10.1007/s11255-016-1350-8. Epub 2016 Jun 27.

PMID:
27349564
11.

The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.

Palmerola R, Smith P, Elliot V, Reese CT, Mahon FB, Harpster LE, Icitovic N, Raman JD.

Can J Urol. 2012 Dec;19(6):6542-7.

PMID:
23228289
12.

The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.

Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.

Eur Urol. 2008 Sep;54(3):581-8. doi: 10.1016/j.eururo.2008.03.104. Epub 2008 Apr 8.

PMID:
18423977
13.

Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.

Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schröder FH.

Eur Urol. 2009 Jan;55(1):139-46. doi: 10.1016/j.eururo.2008.03.079. Epub 2008 Apr 1.

PMID:
18406045
14.
15.

Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?

Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SH, Chung BH.

Yonsei Med J. 2013 May 1;54(3):665-71. doi: 10.3349/ymj.2013.54.3.665.

16.

The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.

van den Bergh RC, Roobol MJ, Wolters T, van Leeuwen PJ, Schröder FH.

BJU Int. 2008 Nov;102(9):1068-73. doi: 10.1111/j.1464-410X.2008.07940.x. Epub 2008 Aug 18.

17.

Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.

Walsh AL, Considine SW, Thomas AZ, Lynch TH, Manecksha RP.

Br J Gen Pract. 2014 Dec;64(629):e783-7. doi: 10.3399/bjgp14X682861.

18.

A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.

Eur Urol. 2013 Apr;63(4):627-33. doi: 10.1016/j.eururo.2012.07.029. Epub 2012 Jul 20.

PMID:
22841675
19.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
20.

The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.

Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH.

Prostate. 2008 Jun 15;68(9):985-93. doi: 10.1002/pros.20759.

PMID:
18409186

Supplemental Content

Support Center